Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Int Operations Lu SafiledCriticalMenarini Int Operations Lu Sa
Priority to PE2005001467ApriorityCriticalpatent/PE20071119A1/en
Publication of PE20071119A1publicationCriticalpatent/PE20071119A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
REFERIDA A UNA COMPOSICION FARMACEUTICA ORAL SOLIDA QUE CONTIENE ZOFENOPRIL O UNA SAL DEL MISMO EN UNA CANTIDAD MAYOR DEL 10% EN PESO DEL TOTAL DE LA COMPOSICION, HIDROCLOROTIAZIDA (HCTZ) EN UNA CANTIDAD MAS DEL 4% EN PESO TOTAL DE LA COMPOSICION Y EXCIPIENTES, DONDE SE PREFIERE LA SAL CALCICA DE ZOFENOPRIL POLIMORFA A PURA DE POLIMORFA DE B. TAMBIEN ESTA REFERIDA A UN METODO DE PREPARACION DE DICHA FORMA DE DOSIFICACION ORAL. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE LA HIPERTENSIONREFERRED TO A SOLID ORAL PHARMACEUTICAL COMPOSITION CONTAINING ZOPHENOPRIL OR A SALT OF THE SAME IN AN AMOUNT GREATER THAN 10% BY WEIGHT OF THE TOTAL COMPOSITION, HYDROCHLOROTHIAZIDE (HCTZ) IN AN AMOUNT OF MORE THAN 4% BY TOTAL WEIGHT, AND EXTENT OF THE COMPOSITION WHERE THE CALCICAL SALT OF ZOPHENOPRIL POLYMORPH IS PREFERRED TO PURE OF POLYMORPH OF B. IT IS ALSO REFERRED TO A PREPARATION METHOD OF SAID ORAL DOSAGE FORM. SUCH COMPOSITION IS USEFUL IN THE TREATMENT OF HYPERTENSION
PE2005001467A2005-12-152005-12-15
PHARMACEUTICAL COMPOSITION CONTAINING ZOPHENOPRIL AND HCTZ FOR THE TREATMENT OF HYPERTENSION
PE20071119A1
(en)
Compounds derived from substituted n- (1h-indazol-5-yl) pyrrolidin-3-carboxamide, erk inhibitors; pharmaceutical composition; and its use in the treatment of cancer.
ARILMETIL-THIAZINAMINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF ALZHEIMER'S DISEASE
COMPOSITE OF (METHANOSULPHONYL -PIPERIDIN) - (ALCOXI-ARIL) -TETRAHIDRO- PYRIDINE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF DIABETES OR OBESITY
Solid preparation comprising 2-ethoxy-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1h-benzimidazole (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl carboxylate, a ph regulating agent and a calcium antagonist compound; and methods for using and improving dissolution of the compound in the solid preparation.
Pharmaceutical composition comprising a salt of strontium and vitamin D and a cyclodextrin, where the mass ratio between the amount of vitamin D and the amount of cyclodextrin is between 1/40 and 1/800, useful for treating or preventing osteoporosis.
2- [3- (2,2-DIFLUORO-BENZO [1,3] DIOXOL-5-ILAMINO) -5- (2,6-DIMETIL-PIRIDIN-4-IL) [1,2,4] TRIAZOL-1 -IL] -N-ETHYL-ACETAMIDE AND ANALOGS OF THE SAME, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESS OF PREPARATION AND USE OF THE SAME IN PSYCHOTIC DISORDERS AND / OR DISEASES WITH INTELLECTUAL DIFFICULTIES.
Piperidine derived compounds; Pharmaceutical composition and use for the treatment and / or prophylaxis of diseases selected from hypertension, congestive heart failure and renal failure, among others.